arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Rallybio Corp

RLYB

$16.22 ▼ -0.05 (-0.34%) at close

7 Visible periods

23 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Weak

Neutral

auto_awesome

Analytical Summary

Rallybio Corp shows mixed fundamentals. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $91.3M

Dividend Yield —

Revenue Growth 43.0%

Op. Margin —

ROIC -57.1% ↗

FCF / Share $-5.30 ↘

Trailing P/E —

Price / Book 1.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

7-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$858.00K

↑ +43.0% —

Net Income Profit after all expenses

$-8.98M

↑ +84.5% —

FCF / Share Free cash flow per share

$-5.30

↓ -367.9% —

Health Breakdown

Returns ↑

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue Growth YoY (%)	43.0% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+438%)	—	—	—	—	—	—
EPS Growth YoY (%)	-19.5% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	27.7% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	12.0% Fair Fair Year-over-year change in earnings per share Optimal: > 10%	-13.6% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—
Net Income Growth YoY (%)	84.5% Excellent ↑ Excellent Improving Year-over-year change in net income	22.5% Good ↑ Good Improving Year-over-year change in net income	-11.9% Weak ↑ Weak Improving Year-over-year change in net income	-41.8% Weak Weak Year-over-year change in net income	-77.8% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-367.9% Weak ↓ Weak Declining Year-over-year change in free cash flow	24.1% Good ↑ Good Improving Year-over-year change in free cash flow	17.3% Good Good Year-over-year change in free cash flow	-0.3% Weak Weak Year-over-year change in free cash flow	—	—	—

💰 Are margins durable? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Effective Tax Rate (%) (%)	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
FCF / Net Income (x)	3.32x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.81x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.86x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.84x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Return on Invested Capital (%)	-57.1% Weak → Weak Stable Return earned on debt + equity capital invested Optimal: > 10%	-77.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-58.7% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-40.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-26.0% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-18.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-53.1% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-88.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-68.3% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-37.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-25.1% Weak Weak Operating profit relative to total assets Optimal: > 10%	-17.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-15.5% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-203%)	-93.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-725%)	-70.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-568%)	-39.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-362%)	-26.8% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-278%)	-19.4% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-230%)	—

⚖️ Is the balance sheet risky? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Interest Coverage (x)	—	—	—	—	-4564.80x Weak Weak Operating income divided by interest expense Optimal: > 5x	-516.39x Weak Weak Operating income divided by interest expense Optimal: > 5x	—
Net Debt (USD)	$-31.37M	$-13.90M	$-24.49M	$-56.96M	$-175.33M	$-140.23M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Revenue per Share (USD)	$0.15	$0.01	—	—	—	—	—
Basic EPS, GAAP (USD)	$-1.59	$-1.33	$-1.84	$-2.09	$-1.84	—	—
Free Cash Flow per Share (USD)	$-5.30	$-1.13	$-1.49	$-1.80	$-1.80	—	—
Book Value per Share (USD)	$10.97	$1.49	$2.81	$4.47	$5.47	$5.81	—
Tangible Book Value per Share (USD)	$10.97	$1.49	$2.81	$4.47	$5.47	$5.81	—
Basic Weighted Avg Shares (shares)	5.63M	43.54M	40.45M	31.82M	25.52M	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Working Capital (USD)	$57.03M	$61.60M	$105.53M	$168.75M	$174.32M	$135.42M	—
Total Equity (USD)	$57.96M	$61.65M	$106.18M	$169.32M	$175.60M	$136.00M	$16.86M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗
Sales/Revenue/Turnover (USD)	$858.00K	$600.00K	—	—	—	—	—
Depreciation Expense (USD)	$100.00K	$100.00K	$100.00K	$200.00K	$100.00K	$62.00K	—
Net Income, GAAP (USD)	$-8.98M	$-57.77M	$-74.56M	$-66.65M	$-47.01M	$-26.45M	—
Operating Cash Flow (USD)	$-29.81M	$-49.28M	$-60.27M	$-57.28M	$-45.53M	$-22.04M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 26 quarters

Rallybio Corp

Analytical Summary

7-Year Financial Trajectory

Health Breakdown

Statement lens

Benchmark Lens

Percentile Rankings

Peer Comparison

Compare RLYB with peers